Barclays Cuts IQVIA (NYSE:IQV) Price Target to $255.00

IQVIA (NYSE:IQV - Get Free Report) had its target price lowered by analysts at Barclays from $275.00 to $255.00 in a research report issued on Friday, Benzinga reports. The firm presently has an "overweight" rating on the medical research company's stock. Barclays's price target indicates a potential upside of 20.65% from the company's previous close.

IQV has been the topic of a number of other research reports. The Goldman Sachs Group started coverage on shares of IQVIA in a research report on Thursday, June 6th. They issued a "buy" rating and a $270.00 target price on the stock. Truist Financial cut their price objective on IQVIA from $297.00 to $292.00 and set a "buy" rating on the stock in a report on Friday, May 3rd. Robert W. Baird cut their price objective on IQVIA from $254.00 to $245.00 and set a "neutral" rating on the stock in a report on Friday, May 3rd. Evercore ISI cut their price objective on IQVIA from $275.00 to $250.00 and set an "outperform" rating on the stock in a report on Friday, May 3rd. Finally, StockNews.com downgraded IQVIA from a "buy" rating to a "hold" rating in a report on Friday, June 21st. Four investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, IQVIA presently has an average rating of "Moderate Buy" and an average price target of $257.73.

IQVIA Price Performance

Shares of IQV traded down $1.40 during trading hours on Friday, hitting $211.35. 5,448,174 shares of the stock were exchanged, compared to its average volume of 1,063,493. IQVIA has a 12-month low of $167.42 and a 12-month high of $261.73. The company has a debt-to-equity ratio of 2.02, a quick ratio of 0.88 and a current ratio of 0.88. The stock's 50-day moving average price is $223.93 and its two-hundred day moving average price is $230.06. The company has a market cap of $38.51 billion, a price-to-earnings ratio of 28.87, a price-to-earnings-growth ratio of 1.92 and a beta of 1.53.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The medical research company reported $2.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.19 by $0.11. The company had revenue of $3.74 billion during the quarter, compared to analysts' expectations of $3.69 billion. IQVIA had a net margin of 9.01% and a return on equity of 29.17%. Research analysts expect that IQVIA will post 10.11 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. Norges Bank purchased a new stake in shares of IQVIA in the 4th quarter valued at about $383,705,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its holdings in shares of IQVIA by 339.6% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,067,195 shares of the medical research company's stock worth $478,308,000 after acquiring an additional 1,597,003 shares during the period. Morningstar Investment Services LLC grew its holdings in shares of IQVIA by 96.9% in the 4th quarter. Morningstar Investment Services LLC now owns 1,231,916 shares of the medical research company's stock worth $286,704,000 after acquiring an additional 606,333 shares during the period. Capital Research Global Investors grew its holdings in shares of IQVIA by 42.2% in the 4th quarter. Capital Research Global Investors now owns 1,995,269 shares of the medical research company's stock worth $461,675,000 after acquiring an additional 592,372 shares during the period. Finally, Cadian Capital Management LP acquired a new stake in shares of IQVIA in the 4th quarter worth approximately $70,108,000. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.